Литература. 
Оппортунистические инфекции в ревматологии

• 1. Зайкова Э. Ф., Редькин Ю. В., Долгих Т. И., Сафонов А. Д., Кудря О. А., Томилова Л. А. Опорные клинические критерии первичной диагностики оппортунистических инфекций. В сб. Оппортунистические инфекции: проблемы и перспективы. Омск: Омская медицинская академия, 2002: 11−14.
• 2. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg MC; CORRONA Investigators. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010;69(2):380−6.
• 3. Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis. 2002; 61(3):251−3.
• 4. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15): 1098−1104.
• 5. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003; 48(8): 2122−2127.
• 6. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005; 52(7): 1986;1992.
• 7. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lorthololary O, Mariette X; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009; 60(7):1884−1894.
• 8. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A; B S R B R Control Centre Consortium, Symmons DP; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010; 69(3): 522−8.
• 9. Диагностика туберкулезной инфекции при планировании и проведении терапии блокаторами ФНО-? у больных ревматическими заболеваниями: Пособие для врачей. Ред. М. И. Перельман, Е. Л. Насонов. М., 2008. 40 с.
• 10. Smitten A, Simon T, Qi K et al. Hospitalized infections in the abatacept RA clinical development program: an updated epidemiological assessment with >10.000 person-years of exposure. Arthritis Rheum. 2008; 58(Suppl.9): 308−309.
• 11. Latorre MC, Valero YS. Rituximab in patients with rheumatoid arthritis and disseminated and latent tuberculosis: long term follow up. Ann Rheum Dis 2009; 68(Suppl 3): 560.
• 12. Van Vollenhoven RF, Nishimoto N, Yamanaka H, Woodworth T, Schiff MH, Taylor A, Pope JE Experience with mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety database. Ann Rheum Dis 2009;68(Suppl 3):567.
• 13. Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, Tesser J, Posever J, Miller M, Araujo J, Kageyama DM, Berry M, Karl L, Yung CM. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 2004;50(6):1959;66.
• 14. Данные на сайте: www.fda.gov
• 15. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002; 46(10): 2565−70.
• 16. Bourre-Tessier J, Fortin C, Belisle A, Desmarais E, Choquette D, Senecal JL. Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept. Scand J Rheumatol. 2009;38(4):311−6.
• 17. Gonzalez LA, Vasquez G, Restrepo JP, Velasquez M, Ramirez LA. Cryptococcosis in systemic lupus erythematosus: a series of six cases. Lupus. 2010; 19(5): 639−45.
• 18. Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007; 26(5): 663−70.
• 19. Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus J Rheumatol. 1996; 23(7):1186−8.
• 20. Lertnawapan R, Totemchokchyakarn K, Nantiruj K, Janwityanujit S. Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int. 2009; 29(5):491−6.
• 21. Hugle B, Solomon M, Harvey E, James A, Wadhwa A, Amin R, Bell-Peter A, Benseler S. Pneumocystis jirovecii pneumonia following Rituximab treatment in Wegener’s Granulomatosis. Arthritis Care Res. Published online: 25 Jun 2010.
• 22. Teichmann LL, Woenckhaus M, Vogel C, Salzberger B, Scholmerich J, Fleck M. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford). 2008; 47(8):1256−7.
• 23. Aoki Y, Iwamoto M, Kamata Y, Nagashima T, Yoshio T, Okazaki H, Minota S. Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases. Rheumatol Int. 2009; 29(11):1327−30.
• 24. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42(4):780−9.
• 25. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis. 2002; 34(8): 1098−107.
• 26. Gerrard JG. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med J Aust. 1995;162(5):233−5.
• 27. Stamp LK, Hurst M. Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol. 2010;37(4):686−8.
• 28. Pena-Sagredo JL, Hernandez MV, Fernandez-Llanio N, Gimenez-Ubeda E, Munoz-Fernandez S, Ortiz A, Gonzalez-Gay MA, Farinas MC; Biobadaser group. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol. 2008;26(5): 854−9.
• 29. Kelesidis T, Salhotra A, Fleisher J, Uslan DZ. Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections? J Infect. 2010; 60(5):386−96.
• 30. Tobon GJ, Serna MJ, Canas CA. Listeria monocytogenes infection in patients with systemic lupus erythematosus. Clin Rheumatol. Published online: 7 March 2010.
• 31. Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune J, Ytterberg SR, Allen NB, Stone JH; WGET Research Group. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med. 2005 Dec;118(12):1416, е9-е18.
• 32. Inanc N, Direskeneli H. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol Int. 2006; 27(1):67−71.
• 33. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, Fraser VJ, Cunningham F, Eisen SA. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis Clin Infect Dis. 2009; 48(10):1364−71.
• 34. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737−44.
• 35. Kinder A, Stephens S, Mortimer N, Sheldon P. Severe herpes zoster after infliximab infusion Postgrad Med J. 2004; 80(939):26.
• 36. Balato N, Gaudiello F, Balato A, Ayala F. Development of primary varicella infection during infliximab treatment for psoriasis. J Am Acad Dermatol. 2009; 60(4):709−10.
• 37. Vonkeman H, ten Napel C, Rasker H, van de Laar M. Disseminated primary varicella infection during infliximab treatment. J Rheumatol. 2004; 31(12): 2517−8.
• 38. Wendling D, Streit G, Toussirot E, Prati C. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine. 2008; 75(5):540−3.
• 39. Balandraud N, Guis S, Meynard JB, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57(5):762−7.
• 40. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet1971;1: 1257−60.
• 41. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009;60(12):3761−5.
• 42. Safety Alerts for Human Medical Products Rituxan (rituximab) — Данные на сайте: www.fda.gov.

Yamamoto M, Takahashi H, Wakasugi H, Sukawa Y, Saito M, Suzuki C, Naishiro Y, Yamamoto H, Shinomura Y, Imai K. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol. 2007;17(1):72−4.

• 43. Kobayashi K, Okamoto Y, Inoue H, Usui T, Ihara M, Kawamata J, Miki Y, Mimori T, Tomimoto H, Takahashi R Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis. Intern Med. 2009;48(15):1307−9.
• 44. Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab the University of North Carolina at Chapel Hill. Arthritis Rheum. Published online: 18 August 2010.